Cybin is trading 5.21% down at $12.55, with the decline appearing mainly tied to biotech-sector weakness.
- XBI is down 2.31% as investors reduce exposure to growth-oriented healthcare stocks amid uncertainty surrounding Federal Reserve Chair Kevin Warsh’s Jackson Hole speech.
- No clear company-specific announcement was identified for August 28, 2026.
- Recent Cybin coverage remains focused on its CEO transition and clinical pipeline, rather than a fresh negative catalyst.